Bayer CT Injection System Offers Wider Range of Compatible CT Contrast Agents, Presentations

Bayer has announced that its MEDRAD Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist (iopromide), Isovue (iopamidol), Optiray (ioversol) and Omnipaque (iohexol). Additionally, Bayer announced the addition of Visipaque (iodixanol) in single-dose vials as Centargo’s fifth compatible contrast agent. This expansion now offers customers in high-throughput imaging suites a wider range of compatible contrast agents and presentations from Centargo.

“We know our customers operating high-volume suites, who serve dozens of patients daily, require flexible and cost-effective solutions to meet their unique needs,” said Jill Carbone, Vice President and Head of Radiology North America Product & Pipeline, Bayer. “The expanded presentations will further support healthcare providers by helping to improve efficiency in end-of-day procedures, providing greater flexibility for those still transitioning to bulk contrast use, and supporting their broad imaging needs with an option to use any of the five leading contrast agents.”

The MEDRAD Centargo CT Injection System helps reduce process and administrative burdens for healthcare providers, enabling them to focus more on patient care, particularly in high throughput settings. By integrating with Bayer’s portfolio of imaging and Cortenic Connectivity workflow solutions, healthcare providers can optimize contrast-usage and enable connectivity to the scanner, hospital radiology information systems and Bayer services.

Powered by Froala Editor